Galenica Financial Statements From 2010 to 2025
| GALNF Stock | USD 116.19 11.19 10.66% |
Check Galenica financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Galenica's main balance sheet or income statement drivers, such as , as well as many indicators such as . Galenica financial statements analysis is a perfect complement when working with Galenica Valuation or Volatility modules.
Galenica |
Galenica AG Company Profit Margin Analysis
Galenica's Profit Margin measures overall efficiency of a company and shows its ability to withstand competition as well as defend against adverse conditions such as rising costs, falling prices, decline in sales or management distress. Profit margin tells investors how well the company executes on its overall pricing strategies as well as how effective the company in controlling its costs.
Current Galenica Profit Margin | 0.04 % |
Most of Galenica's fundamental indicators, such as Profit Margin, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Galenica AG is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, Profit Margin indicator shows the amount of money the company makes from total sales or revenue. It can provide a good insight into companies in the same sector, as well as help to identify trends of a company from year to year.
| Competition |
Based on the latest financial disclosure, Galenica AG has a Profit Margin of 0.0434%. This is 100.39% lower than that of the Healthcare sector and 98.88% lower than that of the Medical Distribution industry. The profit margin for all United States stocks is 103.42% lower than that of the firm.
Galenica AG Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Galenica's current stock value. Our valuation model uses many indicators to compare Galenica value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Galenica competition to find correlations between indicators driving Galenica's intrinsic value. More Info.Galenica AG is rated below average in return on equity category among its peers. It also is rated below average in return on asset category among its peers reporting about 0.33 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Galenica AG is roughly 3.07 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Galenica's earnings, one of the primary drivers of an investment's value.About Galenica Financial Statements
Galenica stakeholders use historical fundamental indicators, such as Galenica's revenue or net income, to determine how well the company is positioned to perform in the future. Although Galenica investors may analyze each financial statement separately, they are all interrelated. For example, changes in Galenica's assets and liabilities are reflected in the revenues and expenses on Galenica's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Galenica AG. Please read more on our technical analysis and fundamental analysis pages.
Galenica AG operates as a healthcare service provider in Switzerland and internationally. The company was founded in 1927 and is headquartered in Bern, Switzerland. Galenica operates under Medical Distribution classification in the United States and is traded on OTC Exchange. It employs 5517 people.
Currently Active Assets on Macroaxis
| DD | Dupont De Nemours | |
| CRDO | Credo Technology Group | |
| GOOG | Alphabet Inc Class C | |
| BAC | Bank of America | |
| CRM | Salesforce |
Other Information on Investing in Galenica Pink Sheet
Galenica financial ratios help investors to determine whether Galenica Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Galenica with respect to the benefits of owning Galenica security.